Redpin Therapeutics has raised $15.5M to advance the development of its ion channel-based chemogenetics platform

BY      |     March 25, 2020

Redpin Therapeutics, a preclinical stage gene therapy company developing proprietary ion channel-based targeted cell therapies that address diseases of the nervous system, announced that it had secured $15.5 million in the initial closing of its Series A financing round.

This fundraise will enable Redpin Therapeutics to advance the development of its groundbreaking ultra-potent ion channel-based chemogenetics platform to address such neurological disorders as epilepsy, neuropathic pain and Parkinson’s disease.

Repin’s approach consists in designing chimeric ligand-gated ion channels as targeted cell therapies to selectively stimulate or inhibit dysfunctional neuronal circuits implicated in a given disease.

Read the press release here.

Read more about Redpin Therapeutics here.

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.